Retrospective study evaluating the performance of a first-trimester combined screening for trisomy 21 in an Italian unselected population
- PMID: 26266002
- PMCID: PMC4510564
Retrospective study evaluating the performance of a first-trimester combined screening for trisomy 21 in an Italian unselected population
Abstract
Objectives: to assess the performance of a combined first-trimester screening for trisomy 21 in an unselected Italian population referred to a specialized private center for prenatal medicine.
Methods: a retrospective validation of first-trimester screening algorithms [risk calculation based on maternal age and nuchal translucency (NT) alone, maternal age and serum parameters (free β-hCG and PAPP-A) alone and a combination of both] for fetal aneuploidies evaluated in an unselected Italian population at Artemisia Fetal-Maternal Medical Centre in Rome. All measurements were performed between 11(+0) and 13(+6) weeks of gestation, between April 2007 and December 2008.
Results: of 3,610 single fetuses included in the study, we had a complete follow-up on 2,984. Fourteen of 17 cases of trisomy 21 were detected when a cut-off of 1:300 was applied [detection rate (DR) 82.4%, 95% confidence interval (CI) 64.2-100; false-positive rate (FPR) 4.7%, 95% CI 3.9-5.4; false-negative rate (FNR) 17.6%, 95% CI 0-35.8%].
Conclusion: in our study population the detection rate for trisomy 21, using the combined risk calculation based on maternal age, fetal NT, maternal PAPP-A and free β-hCG levels, was superior to the application of either parameter alone. The algorithm has been validated for first trimester screening in the Italian population.
Keywords: Down Syndrome; SCA-Test; first trimester screening; nuchal translucency.
References
-
- Nicolaides KH. First-trimester screening for chromosomal abnormalities. Semin Perinatol. 2005;29:190–194. - PubMed
-
- Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10–14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet. 1998 Aug 1;352(9125):343–346. - PubMed
-
- Hormansdorfer C, Scharf A, Golatta M, Vaske B, Hillemanns P, Schmidt P. Preliminary analysis of the new ‘Prenatal Risk Calculation (PRC)’ software. Arch Gynecol Obstet. 2009 Apr;279(4):511–515. - PubMed
-
- Schmidt P, Hormansdorfer C, Pruggmayer M, Schutte C, Neumann A, Gerritzen A, et al. Improved prenatal aneuploidy screening using the novel advanced first-trimester screening algorithm: a multicenter study of 10,017 pregnancies. J Clin Ultrasound. 2008 Sep;36(7):397–402. - PubMed
-
- Schaelike M, Kossakiewicz M, Kossakiewicz A, Schild RL. Examination of a first-trimester Down syndrome screening concept on a mix of 11,107 high- and low-risk patients at a private center for prenatal medicine in Germany. Eur J Obstet Gynecol Reprod Biol. 2009 Jun;144(2):140–145. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous